Subacute Sclerosing Panencephalitis (SSPE)
Transcript of Subacute Sclerosing Panencephalitis (SSPE)
![Page 1: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/1.jpg)
Subacute Sclerosing Panencephalitis (SSPE)
中華民國防疫學會
王任賢 秘書長
![Page 2: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/2.jpg)
Overview
Introduction Virus information and Life Cycle Clinical Features Pathogenesis Subacute Sclerosing Panencephalitis Immune response and persistence Vaccine
![Page 3: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/3.jpg)
Introduction
Genus: Morbillivirus Family: Paramyxoviridae (-)ssRNA virus Highly contagious Lifelong immunity Persistent infections can occur
![Page 4: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/4.jpg)
Introduction
30 million cases, with 345 infant deaths each year
95% of fatal cases in third world countries Malnutrition Secondary infections Low vaccination rates Overcrowding
![Page 5: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/5.jpg)
Virus Information
Enveloped, pleomorphic 100-250nm diameter RNPs= Nucleoprotein Phosphoprotein C + V proteins
Large Polymeraseprotein
![Page 6: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/6.jpg)
Virus Life Cycle
Receptors: CD46 = all nucleated cells CD150 = Activated T and B cells, dendritic cells,
monocytic cells ? = epithelial, endothelial, brain cells
![Page 7: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/7.jpg)
Virus Life Cycle
![Page 8: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/8.jpg)
Budding of the Virus
![Page 9: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/9.jpg)
Symptoms
40oC fever Conjunctivitis Cough Coryza Erythematous maculopapular rash Koplik spots
![Page 10: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/10.jpg)
Transmission
Very contagious from the onset of symptoms until 4 days after the rash
Aerosols or droplets in the air Coughing Sneezing
![Page 11: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/11.jpg)
Complications
Secondary infections due to immunosuppression Pneumonia Respiratory tract infections Gastroenteritis
Encephalitis – APME, MIBE, SSPE Congenital abnormalities or stillbirth during
pregnancy
![Page 12: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/12.jpg)
Treatment
Treat symptoms Plenty of fluids Bed rest Antipyretics
Ribavirin and interferon for particularly severe infections in immunocompromised people
![Page 13: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/13.jpg)
Pathogenesis
Enters through upper respiratory tract Spread to lymph nodes
Infects T cells, B cells, monocytes Causes leukopenia
Can spread to CNS
![Page 14: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/14.jpg)
Pathogenesis
Free virus can infect cells Virus spread by cell fusion Syncytia formation F protein fuses cells together Important but not necessary for infection
MV that cannot fuse can still cause disease
![Page 15: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/15.jpg)
MV Encephalitis
Acute postinfectious measles encephalitis Most frequent = 0.1% of patients 1/5 cases are lethal Can cause permanent neurological damage Autoimmune response in the brain
Measle inclusion body encephalitis Opportunistic infection of the CNS in
immunocompromised patients
![Page 16: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/16.jpg)
Subacute Sclerosing Panencephalitis
Occurs in patients who developed measles under the age of 2
Symptoms appear 7-10 years after infection Risk factors include
Crowding Rural upbringing Mental disabilities
![Page 17: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/17.jpg)
Pathophysiology Thought to immune resistant variant of
measles virus Persistent virus reactivated via unknown
mechanism
![Page 18: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/18.jpg)
Epidemiology Prevalence 0.6 cases/million 1970 0.06
cases/million 1980 (increasing MMR vaccination, MMR licensed in mid 60s)
Incidence 8.5 cases/million cases measles
![Page 19: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/19.jpg)
SSPE: Symptoms
Personality changes, cognitive impairment Head, trunk, limb spasms Abnormal gait, ocular symptoms Coma Death by hyperpyrexia, cardiovascular
collapse, hypothalamic disturbances
![Page 20: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/20.jpg)
SSPE: Viral Defects
Defective M protein Hypermutated and unstable Virions do not assemble Viral spread is by cell fusion Avoids humoral immune response
Can also be caused by H or F defects that affect virion budding
![Page 21: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/21.jpg)
in vitro Mutated M Protein
Cathomen et al generated a ΔM virus
![Page 22: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/22.jpg)
in vitro Mutated M Protein
![Page 23: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/23.jpg)
SSPE: Viral Persistence
Mechanism unknown Anti-MV antibodies can change virus
expression More syncytia formation and less budding
Very young children have circulating maternal antibodies
Cell-mediated immune response is underdeveloped in small children Virus stays “under the radar”
![Page 24: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/24.jpg)
SSPE Viral Persistence
![Page 25: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/25.jpg)
Immune Response
MV suppresses the immune response Immunocompetent can still clear the virus CD8+ cells are needed Three parts of immunosuppression Lymphopenia Prolonged Th2 response Reduced T cell proliferation
![Page 26: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/26.jpg)
Lymphopenia
Increased adhesion of lymphocytes to endothelial cells
Apoptosis Duration:
B cells = 6 weeks T cells = 10 days
![Page 27: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/27.jpg)
Lymphocyte Adhesion Assay
![Page 28: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/28.jpg)
Lymphocyte Adhesion Assay
![Page 29: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/29.jpg)
Th2 Response
Switches after the rash clears Allows maturation of B cells Lifelong immunity
Antibody immune response is less effective than cell mediated Agammaglobulinic children have the same
disease course as normal children
![Page 30: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/30.jpg)
Lack of T cell Proliferation
Suppresses IL-12 Increases Treg production Downregulates CD150 receptor Reduces T cell proliferation
Suppresses IFNα/β
![Page 31: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/31.jpg)
Natural History Typical pt under 20 yrs old SSPE usually develops 7-10 yrs after primary
infection Early infection (< 2 yrs age) is RF Possible to develop SSPE after vaccine (live
attenuated) Potentially worsened by pregnancy due to
immune alterations
![Page 32: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/32.jpg)
Clinical Stages I: personality changes, lethargy, scholastic probs,
unusual behavior. Weeks to yrs II: myoclonus, progressive dementia, sz III: complete neurologic deterioration, flaccidity,
autonomic dysfxn
![Page 33: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/33.jpg)
Differential Dx Viral encephalitis: HSV, arbovirus, West Nile,
enterovirus, echovirus, coxsackie Paraneoplastic encephalitis (may precede
tumor appearance by months or yrs) Postinfectious encephalitis: MMR, influenza,
EBV, VZV Prion dz
![Page 34: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/34.jpg)
SSPE: Diagnosis & Treatment Diagnosis is based on an EEG and high
gammaglobulin levels in the CSF Survival is 1-3 years, 18 months average Treatments: Isoprinosine (panbiotic) = increases CD4+, NK
function, production of IL-1 and IL-2 IFN-α = may suppress viral replication Ribavirin = antiviral drug
![Page 35: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/35.jpg)
Diagnosis Imaging: not terribly helpful, can see focal
abnormalities in subcortical WM
EEG: for once, quite useful
CSF: also, extremely helpful. Sp Ab, of course, but also IgG pattern
![Page 36: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/36.jpg)
EEG
[from NEJM 2007: 357;6, pg. 595]
“Burst-suppression” pattern (2-3s of high voltage delta waves followed by flatpattern) seen only in SSPE or CJD.
![Page 37: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/37.jpg)
CSF
Normal CSF albumin: serum albumin ratio (i.e., normal blood-brain barrier function)
Markedly increased CSF IgG (in this patient, CSF IgG index was 2.7, 4x upper limit nl)
Only a few things that can cause highly elevated CSF IgG response with intact BBB: syphilis, rubella panencephalitis, SSPE
[from NEJM 2007: 357;6, pg. 595]
![Page 38: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/38.jpg)
Treatment Antivirals: lamivudine, ribavirin Interferon alpha (intrathecally) Inosine pranobex (immunomodulatory
antiviral agent, not approved in U.S. Obtained from Canada under IRB for this pt)
![Page 39: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/39.jpg)
Prognosis Not good. Universally fatal if dx in Stg 2.
Death typically within 3 yrs.
Remission possible in stg I with treatment, but still only about 5% rate.
![Page 40: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/40.jpg)
Vaccine
Available in 1963 Combined with mumps and rubella Adapted M protein
Increased virion production Reduced syncytia formation
Given at 15 months, with a booster later Side effects: mild rash, slight fever
![Page 41: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/41.jpg)
Vaccine
Infection in USA has decreased by over 99% Most cases are linked to travel, lack of
immunization 90% decline in Eastern Mediterranean and
Sub-Saharan Africa 74% decline worldwide
Still a burden in malnutrition prone areas
![Page 42: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/42.jpg)
Summary
(-)ssRNA virus causing fever, rash, cough Very easily spread through saliva contact Infects many different types of cells Syncytia formation Virus reduces budding due to maternal
antibodies Infant does not have a strong enough cell
mediated immune response
![Page 43: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/43.jpg)
Summary
Persistence leads to SSPE over many years Causes immunosuppression by lymphopenia,
induction of Th2 and reduction of T cell proliferation
Can be prevented by vaccination – but not if child is under 15 months
![Page 44: Subacute Sclerosing Panencephalitis (SSPE)](https://reader031.fdocuments.in/reader031/viewer/2022020706/61fc80a48d33c02b785decc9/html5/thumbnails/44.jpg)
懇請賜教